Adeona Becomes Synthetic Biologics, Inc. -- New Name Reflects Biotechnology Company Focus on the Emerging Field of Synthetic Biologics -- -- New NYSE Amex Ticker Symbol: SYN -- PR Newswire ANN...
Adeona CEO to Present at the Harvard Investors Group Forum PR Newswire ANN ARBOR, Mich., Feb. 9, 2012 ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN...
Adeona Appoints C. Evan Ballantyne as Chief Financial Officer -- Former CFO of Clinical Data, Inc. Brings Extensive Financial Background to Emerging Synthetic Biologics Company -- PR Newswire ANN...
Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus -- Adeona Chairman, Jeff Riley, Appointed New...
Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis PR Newswire ANN ARBOR, Mich., Jan. 19, 2012 ANN ARBOR, Mich., Jan. 19, 2012...
Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development -- Name Change Reflects Primary...
• Jos. A. Bank (NASDAQ:JOSB) posted Q3 EPS of $0.54, higher than the Zacks Consensus Estimate of $0.51 per share. Revenues increased 21% year over year to $209.6...
Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator -- PNA Center for Neurological Research Clinical Study Results Presented at the 22nd International Symposium on...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |